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Abstract
Signaling through G protein-coupled receptors (GPCRs) mediates numerous airway smooth muscle 
(ASM) functions including contraction, growth, and "synthetic" functions that orchestrate airway 
inflammation and promote remodeling of airway architecture. In this review we provide a 
comprehensive overview of the GPCRs that have been identified in ASM cells, and discuss the extent 
to which signaling via these GPCRs has been characterized and linked to distinct ASM functions. In 
addition, we examine the role of GPCR signaling and its regulation in asthma and asthma treatment, 
and suggest an integrative model whereby an imbalance of GPCR-derived signals in ASM cells 
contributes to the asthmatic state.
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Introduction
G protein coupled receptors (GPCRs) comprise a super-
family of proteins capable of transducing a wide range of
extracellular signals across the plasma membrane of the
cell into discrete intracellular messages capable of regulat-
ing numerous, diverse cell functions. Over 800 GPCRs
have been cloned to date and over 1000 are suspected in
the human genome [1]. The majority of all prescribed drugs
target either activation of GPCRs or their downstream sig-
nals. This holds true for drugs used in the management of
airway diseases such as asthma; it is generally accepted
that GPCRs on airway smooth muscle (ASM) are the direct
targets of the majority of anti-asthma drugs.
Until recently most research efforts examining GPCR ex-
pression, function, and regulation in ASM have focused on
those receptors capable of dynamic regulation of ASM
contractile state and consequently, airway resistance.
However, the growing appreciation of ASM as a pleiotropic
cell capable of regulating airway resistance via "synthetic
functions" has provided a much wider context in which to
consider the relevance of numerous ASM GPCRs. GPCRs
whose activation has little or no direct impact on contractile
state may instead modulate ASM growth or the secretion of
various cytokines, chemokines, eicosanoids, or growth fac-
tors that orchestrate airway inflammation through actions
on both mesenchymal and infiltrating cells. These effects
may ultimately influence airway resistance by: 1) promoting
airway remodeling that impacts the mechanics of ASM con-
traction in vivo; or 2) regulating the inflammatory response
to either disrupt the balance of local pro-contractile/relax-
ant molecules or alter electro- or pharmaco-mechanical
coupling in ASM. Accordingly, it is no longer permissible to
judge the relevance of a given ASM GPCR based on its
ability to dynamically modulate ASM contractile state and
airway resistance. Indeed, our newfound appreciation of
multiple experimental endpoints defining ASM function has
aided efforts to identify relevant ASM GPCRs and their sig-
naling properties.
In this review we will summarize the signaling and function-
al effects of various GPCRs that have been identified in
ASM cells. In addition, we will consider how the regulation
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(or dysregulation) of GPCR signaling potentially impacts
asthma pathogenesis and treatment.
Models for analyzing GPCR signaling in ASM
Models for analyzing GPCR signaling in ASM run the spec-
trum of integrative to reductionist approaches, each having
certain advantages and disadvantages. Integrative in vivo
models in which GPCR ligands are administered systemi-
cally or through inhalation can suggest the presence of
ASM GPCRs capable of mediating bronchoconstrictive or
relaxant effects. Such experiments can provide important
insight into the role of a given GPCR in regulating lung re-
sistance, and suggest the utility of targeting a receptor in
order to control bronchospasm. However, the direct target
cell of delivered agents is often unclear, and frequently the
response of ASM is secondary to actions on other cell
types. For example, inhaled agents can provoke the release
of bronchoreactive substances from multiple cell types that
in turn engage ASM GPCRs, or regulate autonomic control
of ASM contraction through actions on pre- or post-gangli-
onic neurons or reflex arcs [2–4].
A more controlled environment in which to characterize
ASM GPCRs is provided by ex vivo analyses of tracheal or
bronchial smooth muscle isolated as strips or as part of a
complex including cartilaginous ring. This approach reduc-
es, but does not eliminate, neural or paracrine effects on
ASM that can dominate functional ASM responses in vivo.
Such effects can persist because preparations still include
autonomic effector and sensory nerve fiber endings, epithe-
lium, fibroblasts, and blood cells capable of releasing con-
stricting/relaxing agents in response to exogenous agents
or, possibly, mechanical forces [5]. Consequently, intelli-
gent design of such ex vivo analyses can help clarify the in
vivo effects of numerous agents and identify their target
cells. For example, immunohistochemical analysis and tis-
sue bath mechanics of excised ASM strips suggest that the
pronounced bronchoconstriction elicited by inhaled adeno-
sine or adenosine monophosphate in asthmatic subjects or
sensitized animals can be attributed primarily to histamine
release from mast cells in close proximity to or imbedded in
ASM tissue [6–11].
Arguably, the development of ASM cell cultures has provid-
ed the most reliable system for identifying and characteriz-
ing ASM GPCRs. Typically generated by enzymatic
dissociation of ASM cells from sections of tracheae or
bronchi, ASM cultures provide a pure population of ASM
cells that can be greatly expanded, and thus are amenable
to extensive pharmacological, biochemical, and molecular
analyses not possible in vivo or with tissues [12,13]. Cells
of ASM cultures of several species (including human, ca-
nine, bovine, guinea pig, and mouse) have been shown to
be morphologically and functionally similar to ASM in vivo;
they stain for smooth muscle-alpha-actin and myosin heavy
chain, and exhibit signaling and functional responses that
are consistent with ASM function observed or suspected in
vivo [12–15].
The power of ASM cultures as an experimental model ca-
pable of verifying existing and identifying new signaling par-
adigms, while also establishing their physiologic relevance,
is under-appreciated. This power is largely attributed to the
fact that ASM cells possess physiologic levels of most sig-
naling components (e.g., receptors, effectors, and down-
stream signaling intermediates), yet many signaling
pathways are readily characterized with robust signal to
noise ratios. Most importantly, numerous ASM cell func-
tions (including growth, synthesis/secretion of autocrine/
paracrine factors, and to a limited extent, contraction) are
also easily quantified and can be linked to their associated
signaling events. In many other cell culture systems such
linkage of signaling to relevant cell function cannot be
achieved. For example, the majority of studies revealing
novel receptor-mediated signaling paradigms have utilized
expression systems such as COS or HEK293 cells to ex-
press recombinant receptors or signaling components in
order to delineate pathway interactions and their modes of
regulation. It is unclear whether such paradigms occur un-
der relevant conditions in which most signaling compo-
nents are expressed at low levels and their actions may be
constrained by compartmentalization [16,17]. Moreover,
whether such signaling has any relevance to cell function is
unclear, because such cells typically either lack discrete
measurable functions or their functions are known to be
dysregulated (e.g., physiologic regulation of growth cannot
be studied in a transformed cell). Recent studies [18–20]
have begun testing the applicability and physiologic rele-
vance of various GPCR signaling paradigms in cultured
ASM cells.
However, ASM cultures as a model system are far from per-
fect. That ASM cells in culture lack the context of the in vivo
condition is not only a strength but also an inherent limita-
tion of this reductionist model. Moreover, like most primary
cells grown in culture, ASM cells undergo a degree of de-
differentiation that coincides with a loss or increase in vari-
ous signaling elements and functional apparatus [3]. Spe-
cific changes in ASM cells relevant to GPCR signaling that
are known to occur in culture include a rapid and progres-
sive decrease in the expression of Gq-coupled receptors
such as the m3 muscarinic acetylcholine receptor (m3
mAChR) [21] and the cysteinyl leukotriene type 1 receptor
(CLT1R; Stuart Hirst, personal communication). In addition,
contractile function of cultured ASM cells is rapidly dimin-
ished, coinciding with reduced expression of smooth mus-
cle alpha-actin and myosin heavy chain, calponin, h-
caldesmon, beta-tropomyosin, and myosin light chain ki-
nase (MLCK) [22]. However, Shore, Fredberg, and col-
leagues have developed a model for examining agonist-Available online http://respiratory-research.com/content/4/1/2
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induced changes in stiffness of cultured ASM cells that has
provided useful information linking regulation of GPCR sig-
naling with ASM contractile state [23]. Interestingly,
Stephens [24], Halayko, Solway [25–27], and colleagues
have demonstrated that prolonged serum starvation of cul-
tured canine ASM cells can beget a subpopulation of cells
that reacquire high m3 mAChR and contractile/cytoskeletal
protein expression and thus contractile function. These
findings suggest a potentially powerful strategy for deline-
ating elements critical to Gq-coupled receptor signaling
and pharmaco-mechanical coupling in ASM.
Gq-coupled receptors
Although numerous GPCRs have the ability to couple to
more than one heterotrimeric G protein, a given GPCR is
typically classified based on the G protein subfamily (e.g.,
Gs, Gi/o, or Gq/11) it preferentially activates. A diagram of
Gq-coupled receptor signaling, and the associated func-
tional outcomes in ASM, is provided in Fig. 1. Signaling via
Gq-coupled receptors in ASM is of particular interest due
to its prominent role in promoting ASM contraction. Trans-
membrane signaling occurs in the classical GPCR-G pro-
tein-effector protein paradigm. An agonist-bound receptor
undergoes a conformational change that promotes its as-
sociation with and activation of the heterotrimeric G protein
Gq. The extreme C-terminus of the G alpha subunit is the
receptor recognition domain and dictates receptor-Gα
specificity. Receptor-Gα association promotes the release
of GDP from Gα and binding of GTP. The active GTP-
bound Gα dissociates from Gβγ and in turn activates an ef-
fector molecule. The Gβγ heterodimer (numerous combina-
tions of 7 different β and 12 different γ subunits exist) also
has the capacity to regulate the activity of various effectors
and numerous other signaling elements (discussed below).
The duration of one cycle of receptor activation of effector
is dictated by the GTPase activity of Gα, as the hydrolysis
of GTP to GDP promotes reconstitution and membrane lo-
calization of the Gαβγ trimer. Traditionally, alpha subunit
GTPase activity was presumed "intrinsic", but it is now ap-
preciated that this activity can be regulated by GTPase pro-
teins (GAPs) in a manner similar to that demonstrated for
small G proteins [28]. Phospholipase C (PLC) is the prin-
cipal effector of Gq-mediated signaling. Eleven different
isoforms of PLC exist and exhibit distinct patterns of regu-
lation; members of the PLCβ subfamily tend to mediate the
actions of activated Gq [29]. Activated PLC hydrolyzes
phosphoinositol 4,5-bisphosphate (PIP2) into 1,2-diacylg-
lycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). The
net effect of increased IP3 and DAG levels is to increase in-
tracellular Ca2+ through release from internal stores and in-
flux from membrane-bound channels [3], and in ASM to
activate the cell's contractile machinery through both Ca2+
and protein kinase C (PKC) -dependent mechanisms [30–
33] (see Fig. 1 Legend for details).
Studies of agonist-induced increases in airway resistance,
smooth muscle contraction ex vivo, and receptor binding
and second messenger analyses of cultured ASM cells
have helped identify numerous Gq-coupled receptors in
ASM (Table 1). Resting ASM tone in vivo is determined pri-
marily by parasympathetic cholinergic innervation acting on
ASM m3 mAChRs. Other ASM Gq-coupled receptors ca-
pable of inducing significant ASM contraction (in vivo or ex
vivo) include the H1 histamine receptor, CLT1R, B2 brady-
kinin receptors, and ET-A endothelin receptor. Additional
Gq-coupled receptors such as the A3 adenosine, NK-1,
NK-2 (Neurokinin-1 and -2) and P2 purinergic have been
identified, but their importance in mediating contraction un-
der physiologic or pathologic conditions is unclear. In some
cases the evidence for their expression in ASM is either in-
direct or is difficult to interpret given the labile nature of Gq-
coupled receptor expression in ASM cultures.
However, as noted above ASM cells do more than contract
and studies of other functional outcomes in ASM suggest
a potentially important role for numerous Gq-coupled re-
ceptors in modulating ASM synthetic functions. Both
thrombin (capable of activating Gq through protease-acti-
vated receptors (PARs) [34]) and lysophosphatidic acid
(LPA) (capable of activating Gq through endothelium differ-
entiation gene (EDG) receptors) are strong stimulators of
cultured ASM DNA synthesis and cell proliferation. These
effects appear in part Gq-dependent (Billington and Penn,
unpublished observations) and may be mediated by the ca-
pacity of Gq signaling to stimulate the p42/p44 MAPK (via
PKC-mediated phosphorylation of Raf-1) and p70S6K
pathways and therefore induce promitogenic transcription
factor activation, cyclin D1 induction, and upregulate the
translational machinery necessary for cell cycle progres-
sion [36,37]. Moreover, numerous Gq-coupled receptor
agonists including thrombin, lysophosphatidic acid, leukot-
riene D4 (LTD4), endothelin, histamine, thromboxane (acti-
vating Thromboxane A2 / Prostaglandin (TP)
receptors)[19], and sphingosine-1-phosphate (SPP) (acti-
vating EDG receptors) have been shown to potentiate the
mitogenic effects of receptor tyrosine kinase signaling, al-
though it has not been established that Gq activation per
se mediates this effect.
Gq-dependent activation of PKC and p42/p44 also pro-
motes phosphorylation and activation of phospholipase A2
(PLA2), which contributes to rapid eicosanoid synthesis in
ASM cells stimulated with bradykinin (acting on B2 brady-
kinin receptors)[39]. Other effects reported to involve Gq
activation by ASM GPCRs include actin polymerization in-
duced by LPA, endothelin, or carbachol, which appears to
occur via a Rho-dependent mechanism [40]. This suggests
that effectors other than PLC can be directly activated by
Gq in ASM.Respiratory Research   Vol 4 No 1   Billington et al.
Figure 1
Gq-coupled receptor signaling in airway smooth muscle. Airway smooth muscle (ASM) is innervated by postganglionic parasympathetic nerves 
that release acetylcholine (acting on m3 mAChRs) to control resting ASM tone. In addition to the m3 muscarinic acetylcholine receptor (mAChR), 
other Gq-coupled coupled receptors are expressed in ASM (see Table 1), and can similarly mediate contraction and other depicted ASM functions. 
Transmembrane signaling of G protein-coupled receptors (GPCRs) involves sequential activation of receptor, G protein, and effector. Upon agonist 
binding, the receptor undergoes a conformational change exposing a high-affinity binding site for a G-protein in its GDP-bound inactive state. The 
receptor specifically interacts with the C-terminus of the α subunit of the G-protein heterotrimer. G-protein binding to receptor releases the nucle-
otide leaving an empty nucleotide binding pocket readily occupied by GTP, which exists at a higher cytosolic concentration than GDP. This 
exchange of the G-protein-bound GDP for GTP induces a conformational change in the switch region of Gα and causes the dissociation of Gα from 
the Gβγ dimer. The Gβ and Gγ subunits are tightly associated and remain anchored into the lipid bilayer due to the prenylation of the Gγ subunit – a 
permanent lipid modification. In the case of Gαq, the GTP-bound Gα q-protein's effector interaction domain is exposed and activates phospholipase 
C (PLC). PLC promotes the hydrolysis of phosphoinositol 4,5-bisphosphate (PIP2) into the intracellular messengers 1,2-diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (IP3). DAG remains membrane bound and promotes the translocation of protein kinase C (PKC) from the cytoplasm to 
the membrane and its subsequent activation. Activated PKC is capable of phosphorylating a number of substrates including calponin; PKC-medi-
ated phosphorylation of calponin results in a loss of calponin's ability to inhibit actomyosin ATPase [30,269]. PKC also phosphorylates intermediates 
of MAPK signaling pathways, which activate various gene transcription factors involved in promoting ASM growth. Gq-coupled receptors are also 
able to impact receptor tyrosine kinase-induced ASM growth via a synergistic activation of p70S6K. Both PKC and p42/p44 MAPK phosphorylate 
and stimulate the catalytic activity of phospholipase A2 (PLA2). Calcium binding to PLA2 triggers its association with the plasma or nuclear mem-
brane and the subsequent cleaving and release of arachadonic acid (AA). The conversion of AA to prostaglandins and thromboxanes is facilitated by 
cyclo-oxygenase-2, a highly regulated enzyme upregulated by pro-inflammatory agents including lipopolysaccharide, cytokines and growth factors. 
The other product of PIP2 hydrolysis, IP3, translocates and binds to IP3 receptors located on sarcoplasmic calcium stores. Activation of IP3 receptors 
results in the opening of Ca2+ channels and calcium efflux into the cytosol. Intracellular calcium stores are the major source of elevated calcium 
mediating ASM contraction, although influx from receptor-operated calcium channels can contribute. The rise in intracellular calcium promotes cal-
cium binding to calmodulin forming calcium-calmodulin complexes that activate myosin light chain kinase (MLCK). MLCK phosphorylates myosin 
light chains and enables actin to activate the myosin ATPase activity required for cross-bridge cycling and contraction. Via its interaction with various 
guanine-nucleotide exchange factors for Rho (RhoGEFs), Gq has also recently been shown to activate the small G protein Rho [270]. In ASM, Gq-
mediated activation of Rho has been implicated in regulating actin cytoskeletal rearrangement [40]. Rho is also a key mediator of calcium sensitiza-
tion – a phenomenon observed following stimulation with numerous GPCRs whereby heightened contractile effects can be induced for a given level 
of calcium mobilization. Rho activates Rho kinase, which in turn phosphorylates the myosin binding subunit of myosin light chain phosphatase 
(MLCP) to inhibit phosphatase activity, resulting in net increased phosphorylation of myosin light chain (MLC) and an associated increase in cross-
bridge cycling [271]. Although activation of G12/13 is most commonly associated with Rho activity, studies of ASM suggest that Gq and Gi can also 
participate in Rho-mediated functions [40,272,273].Available online http://respiratory-research.com/content/4/1/2
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Gs-coupled receptors
Whereas Gq-coupled receptors are the principal media-
tors of ASM contraction, Gs-coupled receptors on ASM
play a central role in promoting relaxation of contracted
ASM and in conferring prophylactic "bronchoprotection".
Inhaled beta-agonists, which activate the Gs-coupled beta-
2-adrenergic receptor (β2AR) on ASM, are the most widely
used agents in asthma therapy and are universally recog-
nized as the treatment of choice for acute asthma attacks.
Several other Gs-coupled receptors, including the E-Pros-
tanoid 2 (EP2) prostaglandin E2 (PGE2) [20], IP prostacy-
clin ([41] and Pascual and Penn, unpublished
observations), A2b adenosine [42], and vasoactive intesti-
nal peptide (VIP)[43] receptors have been identified in
ASM and represent intriguing, albeit elusive, therapeutic
targets (Table 1).
Gs-coupled receptor signaling and its regulation have been
extensively characterized in numerous cells types, including
ASM [44]. The overwhelming majority of studies
delineating the basic tenets of Gs-coupled receptor signal-
ing have examined β2AR signaling, based on the preva-
lence of endogenously expressed β2ARs, the established
relevance of β2ARs in the function of several organ sys-
tems, the existence of highly selective β2AR ligands, and
the early cloning of the β2AR enabling heterologous ex-
pression of the receptor in various cell systems. Figure 2
depicts the most prominent features of Gs-coupled recep-
tor signaling and functional consequences in ASM cells.
Adenylyl cyclase (AC) is the principal effector of Gs-cou-
pled receptor transmembrane signaling. Nine isoforms
(type I through IX) of AC are known to exist [45]. RT-PCR
has identified transcripts of all AC subtypes except III and
VIII in human ASM cultures, although immunoblot analysis
suggests the presence of only V/VI (existing antibodies do
not distinguish between type V and VI), and analyses of AC
regulation in human ASM cultures (discussed below) are
consistent with the expression of AC V and VI [46,47]. In-
terestingly, AC subtype expression in ASM cultures may be
Table 1
GPCR References Couples to Functions in ASM1
Comment
5-HT [125,126,213–215] Gi2 CXN, GP 5-HT2c identified, other subtypes likely
A1 adenosine [42,216,217] Gi CXN Low levels suggested in human ASM
A2b adenosine [42] Gs3 RLXN Mediates effects of autocrine and paracrine 
adenosine
A3 adenosine [218,219] Gq4 unclear
α-1 adrenergic [220–223] Gq unclear Only response in lung or ex vivo occurs with 
βAR antagonist present
β2 adrenergic [56,185,224,225] Gs RLXN, Cyt, GI
BK bradykinin [39,226–231] Gq CXN Robust activation of PLC and PLA2 in cul-
tured ASM;putative B3 yet to be cloned
CLT1R [232–236] Gq CXN, GP CLT1R antagonists most therapeutic of all 
GqCR antagonists
ET-A/B [237–242] Gq CXN, GP
EDG 1–7 [38,243–245] Gq, Gi, G12/13 GS, Cyt Most subtypes exhibit promiscuity toward G 
proteins
EP2 [20,246,247] Gs RLXN, GI, Cyt Indirect evidence for expression of EP1, 
EP3, and EP4
H1 histamine [248,249] Gq CXN, GP Exhibits homologous and heterologous 
desensitization
IP Prostacyclin [41,250] Gs GI Responsive to autocrine PGI2 induced by 
cytokines via COX-2 induction
m2 muscarinic [21,251,252] Gi unclear Mediator of acute adenylyl cyclase inhibi-
tion, chronic sensitization
m3 muscarinic [251–256] Gq CXN, GP Rapid reduction of expression in culture
NK-1/2 [257–260] Gq CXN, GP
PAR-1,2,3 [34,261,262] Gq, Gi, G12/13 GS, GP Thrombin most mitogenic GPCR agonist; 
subtype promiscuity towards G proteins
P2 purinergic [218,219] Gq unclear P1 may also be expressed
TP [41,263–266] Gq, Gi, G12/13 (?) CXN, GP Coupling specificity poorly characterized in 
ASM
VIP [43,267,268] Gs GI
1 Abbreviations: CXN – contraction; Cyt – regulation of ASM cytokine/chemokine synthesis; GI-inhibition of ASM growth (DNA synthesis/cell pro-
liferation); GP – potentiation of growth stimulated by polypeptide growth factors; GS – growth stimulation ; RLXN – relaxation 2 Coupling to Gi is 
suggested by sensitivity of signal transduction or functional effects to pertussis toxin 3 All receptors noted to couple to Gs have been shown to 
stimulate cAMP production in ASM. 4 Coupling of receptors to Gq is suggested by either agonist-stimulated phosphoinositide production or cal-
cium flux.Respiratory Research   Vol 4 No 1   Billington et al.
species specific, as regulatory features of AC in bovine, ca-
nine, and guinea pig ASM suggest prominent expression of
AC II [48–51], whereas a minimal [46] or no [47] level of
AC II transcripts were detected in human ASM (see below).
Adenylyl cyclase isoforms are subject to multiple forms of
regulation (discussed below), although dynamic activation
of AC under physiologic conditions occurs almost exclu-
sively by interaction with Gαs [52]. Gαs activation of AC
Figure 2
Gs-coupled receptor signaling in airway smooth muscle. Gs-coupled receptors on airway smooth muscle (ASM) are activated by endogenous 
agents such as circulating catecholamines, prostaglandins and iso-prostanes, adenosine and vasoactive intestinal peptide (VIP). Activated Gαs 
binds to and activates membrane bound adenylyl cyclase (AC). AC is comprised of eight membrane-spanning α-helices, and two cytosolic domains 
which are required for catalytic activity and integrate various regulatory signals. The cytosolic domains possess specific binding sites for the G-pro-
tein subunits Gαs, Gαi, and Gβγ. Of the nine know AC isoforms, AC V and VI appear be expressed and functionally important in human ASM. Ade-
nylyl cyclase activation catalyzes the formation of cyclic AMP from cytoplasmic ATP. Cyclic AMP is a ubiquitous second messenger whose principal 
function is to activate protein kinase A (PKA). Inactive PKA exists as a complex comprising two regulatory and two catalytic subunits. The high affinity 
binding of cyclic AMP to domains in the regulatory region induces a conformational change forcing the release of the active catalytic subunits. PKA-
mediated phosphorylation of various intracellular proteins has widespread effects in ASM. PKA can phosphorylate certain Gq-coupled receptors as 
well as phospholipase C (PLC) and thereby inhibit G protein-coupled receptor (GPCR) -PLC-mediated phosphoinositide (PI) generation, and thus 
calcium flux. PKA phosphorylates the inositol 1,4,5-trisphosphate (IP3) receptor to reduce its affinity for IP3 and further limit calcium mobilization. 
PKA phosphorylates myosin light chain kinase (MLCK) and decreases its affinity to calcium calmodulin, thus reducing activity and myosin light chain 
(MLC) phosphorylation. PKA also phosphorylates KCa++ channels in ASM, increasing their open-state probability (and therefore K+ efflux) and pro-
moting hyperpolarization. Through its phosphorylation of the transcription factor CREB and its (typically inhibitory) effects on GPCR and receptor 
tyrosine kinase signaling, PKA regulates the transcription of numerous genes. Recent studies suggest that cAMP/PKA mediates regulation of the 
expression of numerous immunomodulatory proteins in ASM including IL-6, RANTES, eotaxin, and GM-CSF [53,54,274–276]. Although poorly 
characterized, the growth inhibitory effect of Gs-coupled receptor activation in ASM is consistent with the known effects of PKA on mitogenic sign-
aling. These effects include inhibition of p42/p44 MAPK signaling via phosphorylation and inhibition of the upstream intermediate raf-1, and via inhi-
bition of promitogenic transcriptional regulation mediated by phospho-CREB. Lastly, Gs-coupled receptor activation is also believed to promote 
PKA-independent effects, including gating of KCa++ channels directly by Gαs [56], and actin polymerization via an unestablished mechanism [55].Available online http://respiratory-research.com/content/4/1/2
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catalyzes ATP to cyclic AMP (cAMP), which in turn binds to
the regulatory subunits of the cAMP-dependent protein ki-
nase (protein kinase A or PKA). The cAMP-bound regulato-
ry subunits then dissociate from and thereby activate the
catalytic subunits of the enzyme, which in turn phosphor-
ylate and regulate the activity of numerous proteins, includ-
ing the transcription factor CREB. PKA activity is presumed
responsible for the majority of cellular actions elicited by
Gs-coupled receptor activation, which in ASM include re-
laxation, altered transcription of numerous genes that
impact airway inflammation and remodeling [53,54], inhibi-
tion of cell growth, and ion channel gating [3]. However,
cAMP/PKA -independent signaling by Gs-coupled recep-
tors has also been proposed and may have important func-
tional consequences in ASM. These include beta-agonist-
induced actin depolymerization [55], direct activation of
Ca2+-sensitive K+ channels by Gαs subunits [56], and
possibly other ill-defined signaling events that promote re-
laxation and are unaffected by exposure of ASM to pharma-
cological inhibitors of PKA [57].
Gi-coupled receptors
The majority of known GPCRs preferentially couple to
members of the Gi family, and Gi appears to be the most
abundantly expressed heterotrimeric G protein in most cell
types. Members of the Gαi family expressed in ASM in-
clude Gαi-1, Gαi-2, and Gαi-3 [58,59]. Gαi activation is
typically associated with inhibition of Gαs-stimulated AC
activity (for certain AC isoforms) and thus reduced cAMP
generation, the functional consequences of which should
be predictable but are often difficult to identify in a wide
range of experimental models [2,60]. However, numerous
other signaling events elicited by Gαi activation, with clear
functional consequences, have recently been identified
(Fig. 3). Gi appears capable of activating Rho through acti-
vation of Rho guanine nucleotide exchange factors (GEFs),
and in ASM this can mediate both actin polymerization and
possibly contractile sensitization [40,61]. Whether Gi acti-
vation of Rho is mediated by α or βγ subunits is unclear. βγ
subunits released due to Gi activation are believed to pro-
mote many of the βγ effects identified to date, perhaps re-
flecting the relatively high levels of Gi in most cells that
could provide the levels of free βγ required for its signaling
effect [52]. In in vitro systems βγ subunits have been shown
to enhance the activity of selected AC isoforms stimulated
by Gαs. Moreover, βγ may also mediate, through what may
be an indirect mechanism [62], the AC sensitization ob-
served in neuronal cells chronically exposed to opioids
(contributing to tolerance to morphine [63–65]) and in hu-
man ASM cells chronically treated with carbachol and other
ligands capable of activating Gi-coupled receptors [46].
The purpose of such AC sensitization in ASM is unclear,
but may involve the need to maintain a degree of Gs-cou-
pled receptor signaling in the face of persistent Gi-coupled
receptor activation.
A role for Gi-coupled receptors in modulating growth in
ASM is suggested by studies that demonstrate that pertus-
sis toxin (which ADP-ribosylates and inhibits Gαi) partially
inhibits ASM DNA synthesis stimulated by numerous
GPCR ligands including carbachol (activating the m2
mAChR), LPA, SPP, endothelin, and thrombin [18,38]. The
mechanism mediating Gi-stimulated growth of ASM is un-
clear, although actions of both α and βγ subunits may be in-
volved. Gβγ has the potential to stimulate p42/p44 MAPK
via activation of PLC and PKC, and can also mediate p42/
p44 activation through Src-dependent transactivation of
the epidermal growth factor (EGF) receptor [66]. However,
none of these mechanisms has been established in ASM.
On the contrary, transactivation of the EGF receptor is not
induced by thrombin, carbachol, or LPA in human ASM cul-
tures, and increased p42/p44 MAPK signaling does not
appear to mediate the synergistic effect of several GPCR
agonists on EGF-stimulated ASM growth [18,19]. These
latter findings suggest potentially novel mitogenic signaling
events and define cooperativity between GPCRs and re-
ceptor tyrosine kinases in mediating ASM growth.
G12/13 coupled receptors
Signaling via activation of the G12/13 family has not been
characterized as extensively as has that by other heterot-
rimeric G proteins. The effector molecules that interact di-
rectly with G12 and G13 are not well established, with the
exception of members of a family of guanine nucleotide ex-
change factors for the small G protein Rho [67]. The
GPCRs capable of activating G12 or G13 are also unclear.
Immunoblot analysis demonstrates Gα12 and Gα13 protein
in rat bronchial smooth muscle tissue, and levels are
elevated by repeated antigen challenge (see below)[68]. In
ASM cells, those GPCRs activating G12/13 have not been
characterized, although SPP/LPA-activated EDG recep-
tors, thrombin-activated PAR receptors, and TP receptors
are candidates. The profound effect of inhibitors of Rho and
Rho kinase on GPCR-mediated changes in contractile sen-
sitization [69,70] and actin polymerization [40] strongly
suggest a physiologic role for G12/13 signaling in ASM.
Regulation of GPCR signaling
Signaling by GPCRs is a highly regulated process. One
critical way in which a cell controls its response to extracel-
lular GPCR ligands is through regulation of the expression
and activity of each component of the GPCR-G protein-ef-
fector pathway. Either a loss (desensitization) or increase
(sensitization) in responsiveness of transmembrane signal-
ing components can be evoked to presumably preserve the
cell/organism from excessive signals or ensure detection
and reaction to infrequent or minimal signals. In ASM, stud-
ies of regulation of GPCR signaling have focused on
changes that occur in receptor and G protein expression
and second messenger generation in cells, or on altered
contractile/relaxant effects on ASM in vivo or ex vivo. NoRespiratory Research   Vol 4 No 1   Billington et al.
studies to date have considered the effect of desensitiza-
tion or sensitization of GPCR signaling on GPCR-mediated
functions in ASM other than contraction.
Regulation at the receptor locus
Changes in expression or activity of the receptor represent
a powerful means of regulating GPCR signaling. Altered
GPCR responsiveness can occur via altered receptor den-
sity (up- or down- regulation), modifications of the receptor
such as phosphorylation that diminishes receptor-G protein
interaction (uncoupling), and trafficking of receptor away
from G protein (sequestration/internalization) that enables
either recycling of receptor to a responsive form or facili-
tates receptor loss by lysosomal degradation (Figure 4).
These mechanisms have been characterized extensively in
studies of the β2AR. The degree to which they apply to oth-
er GPCRs is both receptor- and cell-dependent [44]. In
ASM cells, upon exposure to their agonist, both the β2AR
and A2b adenosine receptor undergo rapid desensitization
[42,71,72], which is defined by a loss in agonist-stimulated
cAMP generation, (agonist-specific or homologous desen-
sitization). Rapid beta-agonist-promoted desensitization of
the ASM β2ARs is mediated primarily by receptor phospho-
rylation by G protein-coupled receptor kinases (GRKs)[44],
which specifically recognize the agonist-occupied form of
GPCRs. Numerous GPCRs in various cell types including
ASM [72] have been shown to be regulated by GRKs, and
GRKs themselves are subject to multiple forms of regula-
Figure 3
Gi-coupled receptor signaling in airway smooth muscle. Gi-coupled receptors have the capacity to initiate or modulate signaling through the 
actions of both Gi-derived α and βγ subunits. Activated Gαi dissociates from the heterotrimeric complex and binds to adenylyl cyclase (AC) V and VI 
to act as a negative modulator of Gαs-induced signaling. Gβγ subunits modulate AC activity in an isoform-specific manner, inhibiting AC type I but 
enhancing Gαs-induced activation of AC II, IV and VII. Gβγ can also activate phospholipase C beta (PLCβ) isoforms, resulting in phosphoinositide 
generation, protein kinase C (PKC) activation via 1,2-diacylglycerol (DAG), and calcium mobilization. Through ill-defined mechanisms, Gi-coupled 
receptor activation can also promote airway smooth muscle (ASM) growth [18], and cooperate with both other G protein-coupled receptors 
(GPCRs) [277,278] and receptor tyrosine kinases [19,243] to synergistically stimulate growth. Lastly, Gi activation in ASM can contribute to Rho-
dependent changes in actin polymerization [40,279,280] and calcium sensitization [273], although the mechanism of Rho activation by Gi in ASM 
(or other cell types) is not well established.Available online http://respiratory-research.com/content/4/1/2
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tion, some of which may influence GPCR function in certain
disease states (reviewed in [1]). GRK phosphorylation of
GPCRs partially uncouples the receptor from Gα, and also
promotes binding of arrestin molecules to the receptor,
which more effectively uncouple the receptor from G pro-
tein by sterically inhibiting the receptor-Gα interaction [73].
For numerous GPCRs, GRK-mediated arrestin binding
also initiates receptor internalization/sequestration, which
occurs via the association of the receptor-arrestin complex
with components of clathrin-coated pits [74,75]. GPCR in-
ternalization is not required for GPCR desensitization, but
is required for resensitization, as demonstrated for the
β2AR in ASM [72]. Interestingly, agonist-stimulated arres-
tin-dependent internalization of both the β2AR and A2b ad-
enosine receptor is observed in human ASM cells, whereas
ASM EP2 receptors do not readily bind arrestin, do not ap-
pear to be phosphorylated by GRKs, and do not undergo
rapid agonist-stimulated internalization [20]. Although ASM
EP2 receptors do exhibit desensitization with chronic
PGE2 treatment, they are much more efficacious in stimu-
lating cAMP generation and promoting PKA-dependent
functional effects in ASM cells than are either β2ARs or
A2b adenosine receptors ([20] and Pascual and Penn, un-
published observations). These findings demonstrate the
receptor-specific nature of mechanisms of homologous de-
sensitization, and also show that susceptibility to desensiti-
zation at the receptor locus can be a major determinant in
establishing the effect of GPCR ligands and their receptors
on cellular functions.
GPCRs are also subject to phosphorylation and desensiti-
zation by PKA and PKC. Accordingly, any agent capable of
activating cellular PKA or PKC (e.g., other GPCR agonists,
phosphodiesterase inhibitors) can diminish GPCR respon-
siveness. PKA and PKC-mediated phosphorylation causes
a degree of receptor uncoupling from G protein, but it does
not promote arrestin binding to receptor and rapid internal-
ization. Such heterologous  desensitization of a given
GPCR is typically not as profound as homologous desensi-
tization. Cultured ASM cells exposed briefly to either PGE2,
Figure 4
G protein-coupled receptor regulation in airway smooth muscle. Regulation of G protein-coupled receptor signaling at the receptor locus is 
effected by numerous mechanisms that establish the number and responsiveness of receptors at the cell surface. These mechanisms include new 
receptor synthesis, as well as modes of desensitization and resensitization that unfold after a receptor is activated by agonist. Receptor uncoupling 
occurs as a result of G protein-coupled receptor kinase (GRK) -mediated phosphorylation of agonist-occupied receptor, which promotes arrestin 
binding to phosphorylated receptor and steric inhibition of GPCR-G protein interaction. Arrestin binding to receptor also initiates internalization of 
receptor into clathrin-coated pits, after which receptors can traffick to lysosomes for degradation (downregulation) or be dephosphorylated and recy-
cled back to the plasma membrane (resensitization). In addition, activation of intracellular kinases such as protein kinase A (PKA) or protein kinase C 
(PKC) can also phosphorylate GPCRs and promote a loss of GPCR-G protein coupling. See text for details.Respiratory Research   Vol 4 No 1   Billington et al.
adenosine, forskolin (all stimulators of cAMP production
and PKA activation) or phorbol ester (a PKC activator) ex-
hibit diminished isoproterenol-stimulated cAMP production
[42,46,71,72]. Similarly, chronic exposure of ASM cells to
interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α),
or transforming growth factor beta (TGF-β) also results in
heterologous desensitization of the β2AR, presumably via
the induction of Cyclo-oxygenase-2 (COX-2) activity and
the autocrine effect of induced PGE2 [76–80]. The PGE2-
or IL-1β-mediated loss of beta-agonist-stimulated second
messenger generation is associated with a loss in the relax-
ant effect of beta-agonist on carbachol-contracted ASM
cells in culture [77]. The H1 histamine receptor exhibits
both homologous [81] and heterologous [81]
desensitization, the former presumably mediated exclusive-
ly by GRKs, the latter induced by phorbol ester in a PKC-
dependent manner.
Down-regulation, defined as a loss in receptor density, oc-
curs as a result of increased receptor degradation or re-
duced receptor synthesis. Recovery from GPCR down-
regulation is a relatively slow process and requires new re-
ceptor synthesis. Virtually all GPCRs studied to date under-
go some degree of downregulation when chronically
exposed to their agonist. Other agents can promote a loss
of GPCR density through either inhibition of receptor gene
transcription, or via ill-defined mechanisms that promote re-
ceptor degradation.
Arrestin-dependent internalization of GPCRs has been
identified as a pathway leading to lysosomal degradation of
GPCRs [82]. Recently studies also suggest that β2ARs
and CXCR4 receptors are subject to ubiquitination that ul-
timately directs internalized receptor to lysosomes [83,84],
or in the case of mu and delta opioid receptors, to proteo-
somal degradation [85]. Chronic exposure of ASM cells to
beta-agonist, or ASM tissue to histamine results in down-
regulation of the β2AR [86] and H1 histamine receptor
[87], respectively. The effects of a receptor's agonist and
other agents (e.g., glucocortoids, cytokines, beta-agonists)
on pre- and post-transcriptional regulation of new receptor
synthesis have been characterized for numerous GPCRs in
ASM or lung [81,87–97]. Although receptor degradation
probably plays a prominent role in the down-regulation of
GPCRs in ASM, the trafficking of GPCRs to their degrada-
tion fate has not been studied in ASM cells.
Up-regulation of GPCR expression is also observed for nu-
merous GPCRs in numerous cell types and is an important
physiologic means of conferring sensitization of GPCR sig-
naling. Increased GPCR expression, mediated by
increased gene transcription as well as post-transcriptional
mechanisms, is frequently induced experimentally by chron-
ic treatment of cells with antagonist. Antagonist-mediated
up-regulation of GPCRs is relatively unexplored in ASM
cells or tissue, although chronic treatment of rabbits with
atropine has been shown to up-regulate both m2 and m3
mAChRs in the airway [98]. Transcription regulation of
most GPCR genes in ASM cells is poorly understood, but
should be greatly abetted by the increasing adroitness in
applying molecular techniques to primary ASM cultures
and by the emergence of models of ASM phenotype regu-
lation [27,93].
One final means by which GPCR responsiveness is influ-
enced is by receptor genotype. Single nucleotide polymor-
phisms (SNPs) that result in changes in β2AR expression,
cellular distribution, and signaling have been identified in
both the promoter and coding region of the β2AR gene
[99,100]. SNPs identified in the β2AR promoter have been
shown to affect receptor expression [101,102]. Among
those polymorphisms detected in the coding region,
Arg→Gly16 exhibits enhanced agonist-induced desensiti-
zation (of beta-agonist-stimulated cAMP generation) and
down-regulation, whereas Gln→Glu27 is decidedly desen-
sitization- and down-regulation-resistant. Importantly, these
properties are evident in β2ARs expressed endogenously in
ASM cultures [86]. SNPs identified in other GPCRs (in-
cluding the α2a- [103], α2b- [104], and β1-adrenergic re-
ceptors [105,106]) have also been shown to be of
functional consequence, although their characterization
has been performed primarily in either cell expression mod-
els or in the cardiovascular system.
The relevance of β2AR SNPs to asthma and asthma thera-
py are discussed below.
Regulation at the G protein locus
Regulation of G protein expression and activity has the po-
tential to modify GPCR signaling. Gα subunit GTPase ac-
tivity is known to be regulated by recently discovered RGS
(regulators of G protein signaling) proteins [107]. Experi-
mental manipulation of RGS protein expression can alter
GPCR signaling, but the physiologic role of RGS proteins
is unclear. Interestingly, GRK2 has been recently shown to
contain an RGS domain that can interact specifically with
Gαq and quench its activity [108].
Overexpression of Gα subunits in various cell systems can
enhance GPCR signaling, and the expression of certain Gα
subtypes is altered in various disease state models (see be-
low). In human ASM cells in culture, overexpression of Gαs
increases both basal and Gs-coupled receptor-mediated
cAMP production [46]. Whether altered Gα expression or
localization impacts GPCR signaling under physiologic
conditions is somewhat controversial. Endogenous
expression of G proteins is typically much higher than that
of GPCRs or effectors, suggesting that most GPCR-G pro-
tein-effector signaling is probably limited more by the ex-
pression/activity of the effector or GPCR than by that of theAvailable online http://respiratory-research.com/content/4/1/2
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G protein [109]. However, a growing appreciation that
GPCR signaling may be highly compartmentalized [17]
suggests that even small changes in Gα subtype expres-
sion may regulate GPCR signaling. Consistent with this no-
tion are observations that exposure of lung [110–112],
ASM strips ex vivo [113,114], or ASM cultures [50] to var-
ious agents can elicit a loss of β2AR function that is asso-
ciated with increased expression of specific Gαi isoforms
or decreased expression of Gαs.
Regulation at the effector locus
Although the study of endogenously-expressed GPCR ef-
fectors lags behind that of GPCRs and heterotrimeric G
proteins, the recent cloning of numerous PLC and AC iso-
forms and their analysis in expression systems has facilitat-
ed insight into the tremendous complexity of effector
regulation. Multiple mechanisms by which PLC activity is
regulated have been demonstrated [115]. PLCβ activity is
greatly influenced by substrate availability; the agonist-sen-
sitive pool of PIP2 is metabolized several times per minute
[116], meaning that recycling of products of hydrolysis, and
the activity of numerous enzymes involved in this process,
is critical to PLC activity. Localization of PLC isoforms to
the membrane appears to be regulated by interaction of
pleckstrin homology domains in PLC with specific phosph-
oinositides and Gβγ subunits [117,118]. PLCβ2 and
PLCβ3 isoforms can be phosphorylated by PKA, which re-
sults in reduced activity [119–121]. Other PLC isoforms
can be phosphorylated by PKC, albeit with no apparent
consequence [115,122]. Interestingly, activated PLCβ iso-
forms serve as GTPase-activating proteins for Gαq and
thus participate in negative feedback control of their activa-
tion [123].
Unfortunately our understanding of PLC regulation is de-
rived largely from studies using cell-free models or cellular
expression systems. With the exception of work from Mar-
tin and colleagues [124–126] and Pyne and Pyne [127],
few studies to date have examined PLC signaling and its
regulation in ASM cells.
Studies of AC regulation have been limited by the extremely
low levels of endogenous AC isoform expression, and by
the unstable nature of the AC protein, which has rendered
its purification and characterization problematic. Detection
of endogenous AC protein with currently available antibod-
ies is often difficult in many cell types (including ASM), de-
spite the suggestion of specific isoform expression in
parallel analyses of AC mRNA levels. However, expression
of recombinant AC isoforms has helped identify some reg-
ulatory features of AC [45,128,129]. AC I, II, III, V, and VII
are subject to phosphorylation by PKC, which results in
their sensitization [130–134]. Conversely, phosphorylation
of AC V and VI by PKA inhibits AC activity [135–137]. βγ
subunits potentiate the stimulatory effect of Gαs subunits
on AC II, IV, and VII [138–140]. Calcium/calmodulim is also
a physiologic regulator of AC I, III, and VIII; isoforms whose
expression tends to be restricted to the brain and olfactory
epithelium [128].
Adenylyl cyclase (as well as other elements and regulators
of Gs-coupled receptor signaling) and its activity appear to
be concentrated in lipid rafts or caveolae, suggesting that
compartmentalization serves to facilitate initiation or
quenching of GPCR signaling [141,142]. Similarly, compo-
nents of PLC signaling, but not PLC isoforms themselves,
are also recovered in caveolin-containing membrane frac-
tions [143].
In ASM, AC regulation is evident but appears species-spe-
cific. Stevens et al. [48] and Pyne and Pyne [127,144]
demonstrated that bradykinin, platelet-derived growth fac-
tor (PDGF), and phorbol ester stimulate cAMP formation in
guinea pig ASM, presumably via a PKC-dependent en-
hancement of AC II activation by Gαs. Chronic treatment of
canine ASM cultures with carbachol reduced basal and ag-
onist-stimulated AC activity, an effect that was reversed by
PKC inhibition [51]. Similar results were obtained in stud-
ies of bovine ASM [50]. In contrast, chronic treatment of
human ASM cultures with carbachol (as well as numerous
other agonists of Gi-coupled receptors) promoted AC sen-
sitization but in a PKC-insensitive, pertussis-toxin sensitive
manner [46]. This manner of AC sensitization has been ob-
served in other cell types including neuronal cells treated
chronically with opioids, and appears to be an adaptive re-
sponse (tolerance) to counteract persistent Gi signaling
[64,145,146]. In an analysis of heterologously-expressed
AC isoforms in COS cells, Nevo et al [147] determined that
chronic Gi activation resulted in sensitization of AC I, V, VI,
and VIII, and reduced activity of AC II, IV, and VII. Thus, the
profile of AC transcripts and regulatory features of AC in
human ASM suggest a predominance of AC VI or V in hu-
man ASM, whereas PKC-sensitive isoforms, perhaps AC II,
may be preferentially expressed in non-human ASM.
Aberrant GPCR signaling and airway 
hyperreactivity
Changes in airway structure and ASM contractile state are
the principal causes of increased airway resistance in asth-
ma. Altered airway composition and architecture affect air-
way resistance through mechanisms that are both
independent of and complimentary to changes in ASM con-
tractile state. Excessive mucous production and edema are
physical impediments to conductance, whereas edema
and increased ASM mass alter airway geometry to amplify
the effect of ASM contraction on airway lumen diameter
[148–154].
ASM contractile state can be viewed as a function of: 1) the
net sum of GPCR-mediated signals that result in establish-Respiratory Research   Vol 4 No 1   Billington et al.
ing the level of the key contractile signaling molecule, calci-
um; and 2) the response of the cell's contractile machinery
to calcium. Figure 5 offers a model that proposes 3 levels
at which regulation of GPCR-mediated ASM contraction is
altered in asthma.
Altered GPCR agonist presentation
On one level we can consider the contribution of a disrupt-
ed balance of procontractile and prorelaxant stimuli acces-
sible to ASM, whereby 1) an increase in procontractile
stimuli in the asthmatic airway promotes greater activation
of GPCRs (Gq- and Gi-coupled receptors) mediating con-
traction, or 2) a reduction in agonist levels serving Gs-cou-
pled receptor activation diminishes prorelaxant signaling. It
is well established that numerous GPCR agonists (e.g.,
acetylcholine, histamine, and thromboxane) capable of
evoking ASM contraction are elevated in the airways of
many asthmatics [155–159]. The source of these agonists
may be neural cells (increased parasympathetic discharge
caused by numerous factors) inflammatory cells (e.g., from
mast cells, platelets), or possibly resident mesenchymal air-
way cells (including ASM itself). Exacerbating this condition
in asthma is the sloughing of airway epithelium, which con-
stitutes a loss of diffusion barrier and may increase ASM
access preferentially to procontractile agonists
[152,160,161]. These findings strongly suggest that exag-
gerated procontractile GPCR agonist presentation to ASM
occurs with asthma and contributes to increased ASM
tone. Less certain is whether the levels of prorelaxant
GPCR agonists are suppressed in asthmatics. Such
agents (e.g., catecholamines, certain eicosanoids) tend to
have short half-lives and their local concentrations are not
easily measured. However, it should be recognized that the
loss of airway epithelium in asthma also constitutes a loss
of relaxant factors that target either GPCRs (e.g. PGE2) or
other pathways (nitric oxide) in ASM [152,162–164].
Altered GPCR responsiveness to agonist
On another level we can consider the contribution of al-
tered GPCR responsiveness to a given level of agonist pre-
sented to ASM, such that the sum of GPCR-generated
signals results in higher than normal increases in intracellu-
lar calcium. Such altered GPCR responsiveness may result
from either sensitization of Gq- or Gi-mediated signaling
that promotes increased calcium flux, or from desensitiza-
tion of Gs-coupled receptor signaling that antagonizes sig-
naling leading to elevated calcium. Numerous studies
suggest that both of these phenomena occur and contrib-
ute to ASM hyperresponsiveness.
Recent findings demonstrate that GPCR-mediated con-
traction of ASM strips ex vivo is augmented by various "sen-
sitization" strategies [165]. These strategies include
sensitization to allergen in vivo [68,112,166,167] or prior
exposure of ASM strips ex vivo to cytokines, serum from at-
opic asthmatics, or immune complexes [113,168–172].
Studies of ASM cells suggest that the observed ASM hy-
perreactivity results in part from an increased calcium flux
mediated by sensitized Gq- or Gi-coupled receptor trans-
membrane signaling. Treatment of ASM cells with IL-1β or
TNF-α causes a significantly greater increase in phosphoi-
nositide generation and calcium flux elicited by carbachol,
bradykinin, or thrombin [173–177]. Mechanistic studies
suggest that up-regulated receptor or G protein expression
may mediate this enhanced response. IL-1β and TNF-α are
both able to increase B2 bradykinin receptor expression in
ASM [174,175]. Treatment of ASM ex vivo with cytokines,
rhinovirus, or asthmatic serum [114,171,178], in vivo with
antigen or IL-1β [112,179], or ASM cells in culture with
TNF-α [180], has been shown to increase expression of ei-
ther Gq or specific Gαi isoforms in either lung or ASM.
These latter findings are consistent with the observation in
ASM cells that calcium mobilization stimulated by NaF (a
nonspecific Gα activator) is increased following chronic
treatment with TNF-α, and suggest a mechanism by which
calcium flux stimulated by numerous GPCRs may be aug-
mented [181]. However, it should be noted that the effects
of cytokines on GPCR-mediated PLC activity can be recep-
tor-specific; in the same model that demonstrates TNF-α-
mediated augmentation of bradykinin-stimulated phosphoi-
nositide production, the phosphoinositide response to his-
tamine was depressed, presumably via a COX-dependent,
PKA-mediated phosphorylation and desensitization of the
H1 histamine receptor [175].
The contribution of desensitized prorelaxant Gs-coupled
receptor signaling to airway hyperresponsiveness in asth-
ma is unclear. To date, the β2AR is the only Gs-coupled re-
ceptor whose role in asthma has received significant
attention, and the preponderance of evidence suggests
that β2ARs on ASM are most responsible for the effect of
beta-agonists on airway tone [182]. Whether β2AR dys-
function, and specifically β2AR dysfunction in ASM, plays a
prominent role in asthma has been a hotly debated topic for
over thirty years. Asthma triggers such as viral infections
can diminish β2AR function [183], and numerous animal
models of airway inflammation, ex vivo analyses of ASM
strips treated with cytokines or asthmatic serum [112,114],
and limited data from ASM tissue from severe asthmatics
[184,185] have all provided evidence that β2AR-mediated
relaxant effect and signaling are depressed in asthma. Sev-
eral possible mechanisms by which the proposed dimin-
ished  β2AR function and signaling occurs can be
proposed. The diminished capacity of beta-agonists to in-
hibit methacholine-induced contraction of ASM strips ex
vivo may reflect an increased capacity of m2 mAChRs to in-
hibit beta-agonist-stimulated AC activity (note that asthmat-
ic serum and cytokines upregulate Gαi expression). As
noted above, several studies also demonstrate that numer-
ous agents (e.g. cytokines, TGF-β, PGE2, whose levels areAvailable online http://respiratory-research.com/content/4/1/2
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Figure 5
Model of aberrant G protein-coupled receptor signaling in airway smooth muscle contributing to elevated airway smooth muscle tone. 
Within the context of airway remodeling, G protein-coupled receptor (GPCR) signaling leading to airway smooth muscle (ASM) contraction may be 
altered at 3 different levels in the asthmatic airway. First, ASM may be exposed to greater levels of GPCR agonists that promote contraction (i.e., 
those activating Gq- or Gi-coupled receptors), or to lower levels of GPCR agonists that mediate prorelaxant signaling (Gs-coupled receptors). 
Increased levels of procontractile agonists can augment contraction, whereas combined stimulation of ASM with multiple Gq/Gi -coupled receptor 
agonists has a synergistic effect on contraction [277]. The sources of both procontractile and prorelaxant agonists include infiltrating inflammatory 
cells (e.g., mast cells releasing histamine, platelets releasing thrombin), postganglionic neurons with exaggerated cholinergic discharge resulting 
from stimulated reflex arcs or dysregulated m2 muscarinic acetylcholine receptor (mAChR) -mediated feedback inhibition [281], and resident airway 
cells such as epithelium, fibroblasts, and ASM itself. Access of these agonists to ASM may be increased by sloughing of airway epithelium. Second, 
Gq- or Gi-coupled receptor signaling may be sensitized, or Gs-coupled receptor signaling desensitized, resulting in an imbalance of signaling pro-
moting increased phosphoinositide generation and increased calcium mobilization. Third, the contractile response to calcium may be exaggerated 
due to "augmented sensitization" manifested in increased myosin light chain phosphorylation caused by: 1) an imbalance of GPCR-derived signals; 
and 2) increased expression and activity of myosin light chain kinase (MLCK) associated with inhibited myosin light chain phosphatase (MLCP) 
activity, the latter a result of increased RhoA activity mediated by upregulated G12/13 and RhoA expression. Not included in this model (for the sake 
of simplicity) are other potential regulatory features of ASM contraction including ASM strain and load, direct contribution of non-GPCR signaling 
pathways to phospholipase C (PLC) activation and calcium mobilization, calcium loading in intracellular stores, compartmentalization of calcium and 
calcium signaling, and ion channel and membrane pump activity that directly and indirectly affect intracellular calcium levels.Respiratory Research   Vol 4 No 1   Billington et al.
elevated in the asthmatic airway) induce desensitization of
the β2AR in cultured ASM cells, typically by mechanisms
suggestive of PKA-mediated β2AR phosphorylation. More-
over, intratracheal installation of IL-1β in rats results in not
only a loss of beta-agonist-mediated relaxation of metha-
choline-induced bronchoconstriction, but an increase in
GRK activity, and GRK2 and GRK5 expression in the lung
[112]. This is an intriguing finding and suggests that inflam-
mation may modulate homologous GPCR desensitization
in the airway. This may preferentially affect β2AR signaling
in ASM, in light of findings by McGraw et al. suggesting that
low (endogenous) expression levels of GRKs in ASM cells
account for relatively robust β2AR signaling in ASM [186],
and that such signaling may be sensitive to changes in
GRK [72] or arrestin [20] expression.
In contrast to the evidence cited above, numerous studies
have noted no appreciable loss of β2AR function in asth-
matics based on analyses of lung function, or tissues ex
vivo (reviewed in [2,4,187]). Moreover, β2AR blockade in
normal subjects does not cause bronchoconstriction
[188,189], and the Arg→Gly16 (desensitization-prone)
β2AR polymorphism is not over-represented in asthmatics
[190]. These findings suggest that asthma is not defined by
diminished  β2AR responsiveness. However, constitutive
β2AR signaling does appear to be important in the asthmat-
ic subject, as administration of β2AR antagonists is not well
tolerated in many asthmatic subjects [189]. Predictably, di-
minished β2AR function could influence disease severity.
Results from both clinical trials and epidemiological studies
suggest that β2AR SNPs at codon 16 influence β2AR re-
sponsiveness to both endogenous and exogenous beta-ag-
onists and thereby influence disease severity and response
to therapy [99,191,192]. Asthmatics homozygous for
Gly16 may have fewer responsive β2ARs as a result of
greater down-regulation caused by endogenous catecho-
lamines. Consequently, the effects of endogenous cate-
cholamines and the initial response to exogenous beta-
agonist may be diminished in these patients, as suggested
by data from Martinez et al., demonstrating a significantly
greater bronchodilator response in (beta-agonist naïve)
Arg16 homozygotes [192]. Alternatively, continuous use of
inhaled beta-agonists results in a progressive drop in morn-
ing peak flow only in patients homozygous for the Arg16
SNP [193], suggesting that the absolute loss of β2AR re-
sponsiveness is greater in Arg16 homozygotes because of
their greater capacity to down-regulate from the (naïve) un-
treated state.
Thus the collective evidence suggests that β2AR dysfunc-
tion of any nature does not cause asthma, but the active
disease state likely promotes a loss of β2AR function that
has a small impact on disease severity, at least in some sub-
set of asthmatics. As a corollary, β2AR polymorphisms that
diminish β2AR signaling are disease modifiers, but not dis-
ease predictors, and influence the response to therapy. In
contrast, a more significant role in asthma is suggested for
sensitized Gq or Gi-coupled receptor signal transduction
that promotes a greater phosphoinositide generation and
calcium mobilization in response to a given concentration of
agonist.
Altered responsiveness of the contractile machinery to 
calcium
On a final level we can propose a role for altered respon-
siveness of ASM contractile machinery to calcium as a
mechanism of airway hyperresponsiveness. Although Rho-
mediated sensitization to calcium occurs within the context
of ASM contraction under normal conditions, there is evi-
dence that calcium sensitization mechanisms may be
primed ("augmented sensitization") by inflammation. Chiba
et al. noted that acetylcholine-induced isometric tension
was greater in bronchial rings from antigen-challenged rats
compared to that from control rats, although no significant
difference between the two groups in calcium mobilization
is observed [194]. Similarly, when calcium concentrations
were clamped to 1 µM in permeabilized bronchial rings,
tension development was greater in rings from allergen
sensitized/challenged rats compared to that from controls
[70]. Changes in the expression of numerous proteins may
underlie this augmentation of calcium sensitization in ASM.
In tracheal and bronchial smooth muscle from ragweed-
sensitized dogs, a constitutive increase in phosphorylation
of myosin light chain 20 (MLC20) associated with in-
creased content and activity of MLCK [195,196], and hu-
man bronchial rings sensitized with allergen ex vivo exhibit
an ~3 fold increase in MLCK expression [197]. RhoA pro-
tein levels are increased, and acetylcholine-induced trans-
location of RhoA to the plasma membrane is significantly
higher in bronchial smooth muscle from airway hyperre-
sponsive versus control rats [70,198]. Finally, Gα12 and
Gα13 (upstream regulators of Rho activity) levels in bron-
chial smooth muscle are also upregulated in hyperrespon-
sive rats [68]. These data suggest that allergen-driven
inflammation up-regulates multiple proteins in the pathway
promoting Rho-dependent calcium sensitization, and that
augmented calcium sensitization may be sufficient to con-
fer airway hyperreactivity in asthma.
Altered GPCR responsiveness with therapy
To further complicate the relationship between GPCR re-
sponsiveness and asthma, evidence suggests that both
glucocorticoids and beta-agonists, the two most widely
used drugs in the treatment of asthma, also regulate GPCR
responsiveness, primarily via changes in receptor expres-
sion and coupling. Glucocorticoids have been shown to up-
regulate β2AR and Gαs expression [89,91,199], counter-
act the β2AR down-regulation induced by beta-agonist
[92], and reverse increases in GRK activity and β2AR de-
sensitization induced in a rat model of airway inflammationAvailable online http://respiratory-research.com/content/4/1/2
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[58]. Conversely, glucocorticoids inhibit expression of NK2
receptors in bovine ASM [94], inhibit m2 mAChR expres-
sion in the airway [200], and inhibit the IL-1β-mediated up-
regulation of B2 bradykinin (BK) receptors in the airway
[201]. Pretreatment of human ASM cells with glucocorti-
coids significantly inhibits histamine-stimulated phosphoi-
nositide production [202]. Thus the sum of effects of
glucocorticoids on GPCR signal transduction components
tends to render ASM less responsive to procontractile
stimuli and more responsiveness to beta-agonists.
Beta-agonist therapy, on the other hand, tends to promote
the sensitization of procontractile GPCR signaling and
desensitization of prorelaxant GPCR signaling, with uncer-
tain clinical relevance. Although conflicting data exist as to
whether beta-agonist therapy exacerbates bronchial hyper-
responsiveness in asthmatics, Mak and colleagues have re-
cently demonstrated that exposure of ASM ex vivo to beta-
agonist up-regulates both NK2 [95] and H1 histamine [90]
receptors, suggesting a mechanism whereby enhanced
procontractile GPCR signaling promotes bronchial
hyperresponsiveness.
Numerous studies have also demonstrated that repeated
use of inhaled beta-agonists results in a loss of the prophy-
lactic bronchoprotection conferred by beta-agonists [203–
206]. In many respects this could be considered a normal
and predictable response, consistent with a physiologic/
teleologic role of β2AR desensitization and the demonstra-
tion of homologous desensitization of ASM β2ARs in
multiple in vivo, ex vivo, and in vitro models. However,
Finney et al. recently observed that lung GRK2 levels were
elevated in rats chronically treated with beta-agonists
[110]. Thus, in a manner similar to that invoked by IL-1β
(see above), chronic beta-agonist therapy may up regulate
the GPCR desensitization "machinery" to further limit the
effect of therapy and possibly exacerbate disease.
Although the clinical relevance of the observed loss of
bronchoprotection has been questioned [207], the collec-
tive evidence suggests that homologous β2AR desensitiza-
tion does occur as a consequence of beta-agonist therapy.
Accordingly, therapies that minimize or counteract β2AR
desensitization, such as glucocorticoids and salmeterol,
may benefit from this property. Glucocorticoids preserve or
enhance β2AR function in the airway through both their
anti-inflammatory actions as well as their direct effects on
ASM β2AR expression and regulation noted above. These
effects may explain in part the positive cooperativity
exhibited by combined beta-agonist and glucocorticoids
therapy. As a low intrinsic activity beta agonist, salmeterol
has limited capacity to promote homologous β2AR desen-
sitization in in vitro models [208,209]; this property in addi-
tion to its lipophilic nature appears largely responsible for
its long-lasting effect. Moreover, daily salmeterol treatment
has little effect on the rescue or prophylactic ability of al-
buterol [203,210].
GPCRs in ASM: What lies ahead
Within the last decade the field of GPCR signaling has ex-
perienced an epiphany with the realization that GPCRs do
more than subserve restricted functions in fully differentiat-
ed cells; they also play important roles in mediating diverse
cell functions such as embryogenesis, tissue regeneration,
and cell proliferation [211,212]. Interestingly, this realiza-
tion coincided with a similarly profound discovery in the
field of asthma research – that ASM not only contracts, but
also performs numerous "synthetic" functions that modu-
late both airway structure and airway inflammation. Not sur-
prisingly, ASM GPCRs are important regulators of many
ASM synthetic functions.
The newfound respective focuses of GPCR signaling and
ASM research suggest an exciting direction for the study of
GPCRs in ASM over the next decade. The current chal-
lenge (or curse) confronting the student of ASM signal
transduction extends beyond defining the myriad intracellu-
lar signaling pathways, their regulation, and their degree of
"cross-talk" with each other, to understanding how these
events occur within an equally complex, dynamic airway
environment.
Such an understanding should not only greatly improve our
knowledge of asthma pathogenesis, but also redefine asth-
ma therapy. With the possible exception of steroids, asth-
ma drugs have been developed and prescribed to prevent
or reverse acute bronchospasm with little consideration of
their effects on ASM synthetic functions and the chronic
nature of asthma. As the roles of airway remodeling and
ASM synthetic functions in asthma pathogenesis become
more clearly established, agents that target the activation
or signaling of various GPCRs that mediate these phenom-
ena will undoubtedly receive greater consideration as pro-
phylactic and therapeutic asthma drugs.
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